DataMEDS AI, Inc. (MEDS) Fair Value 2026

MEDS · Medical Distribution ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.3 /10

32 fundamental signals · 1 models active

Value Trap Risk

SAFE (8/100)

Quick Summary — As of 2026-08-27, DataMEDS AI, Inc. (MEDS) trades at $1.17. QOC: 4.3/10. Value Trap Risk: 8/100 (SAFE). 1/13 models active.

Key Facts

Ticker
MEDS
Price
$1.17
Quality Score
4.3/10
Value Trap Risk
8/100
Models Active
1/13
Last Updated
Strength: PWERM suggests +400.6% upside with 32% confidence
Risk: Below-average Quality Score of 4.3/10 signals weak fundamentals

What Fair Value Does Each Model Give MEDS?

1 Intrinsic Value Models vs. Current Price ($1.17)

Core Models (Unlocked)
Model Fair Value Upside
Option-Based · Medium Conviction
 $5.86 +400.6%

All Models Active

All 1 models are displayed above.

What Is DataMEDS AI, Inc. (MEDS) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, the weight of evidence tilts decidedly bullish for DataMEDS AI, Inc.. Trading at $1.17 against an estimated intrinsic value of $5.86, 1 of 1 active models flag meaningful upside of +400.6% at the median.

What Do the Models Say About MEDS?

1 of 13 models are currently active for MEDS. All 1 active models suggest the stock trades below fair value. See which stocks rank higher →

How Does MEDS Rank in Medical Distribution?

Among 13 Medical Distribution stocks, MEDS ranks #11 by Quality of Company score. CirclFi's QOC score of 4.3/10 evaluates 32 fundamental signals. A score of 4.3 reflects mixed fundamentals.

DataMEDS AI, Inc. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is MEDS a Value Trap?

CirclFi's Value Trap algorithm assigns MEDS a score of 8/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for DataMEDS AI, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, DataMEDS AI, Inc.'s fundamental quality profile registers 4.3/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every MEDS valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across MEDS's 1 active models, average confidence is 32%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy DataMEDS AI, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Distribution Stocks Should You Also Analyze?

9 related Medical Distribution stocks with 13-model coverage

COSMCosmos Health Inc.QOC 4.5HKPDCellyan Biotechnology Co., LtdQOC 2.5SNYRSynergy CHC Corp.QOC 4.6AHGAkso Health GroupQOC 2.2VNOVVNOVQOC 5.6MCKMcKesson CorporationQOC 8.7HSICHenry Schein, Inc.QOC 7.3FOCLEDAP TMS S.A.QOC 5.8CORCencora, Inc.QOC 8.3

Read investment analysis: COSM · HKPD · SNYR · AHG · VNOV · MCK · HSIC · FOCL · COR

Which Other Stocks Have a Similar Quality Score to MEDS?

7 companies across all industries closest to MEDS’s Quality of Company score of 4.3/10.

NXENexGen Energy Ltd.QOC 4.3SATTSativus Tech Corp.QOC 4.3FABCFabric.AI, Inc.QOC 4.3CLDICalidi Biotherapeutics, Inc.QOC 4.3FBRXForte Biosciences, Inc.QOC 4.3RGNTRegentis Biomaterials Ltd.QOC 4.3NVDANVIDIA CorporationQOC 10.0

Read investment analysis: NXE · SATT · FABC · CLDI · FBRX · RGNT · NVDA

What Else Do Investors Ask About DataMEDS AI, Inc.’s Valuation?

What is DataMEDS AI, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for DataMEDS AI, Inc. (MEDS). The Quality of Company score is 4.3/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is MEDS overvalued or undervalued right now?

At $1.17, 1 of 1 active models suggest MEDS may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits DataMEDS AI, Inc.'s business model in Medical Distribution.

What does a Quality of Company score of 4.3 mean for MEDS?

DataMEDS AI, Inc.'s QOC of 4.3/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on MEDS?

CirclFi analyzes MEDS with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is MEDS a value trap in 2026?

DataMEDS AI, Inc.'s Value Trap score is 8/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns DataMEDS AI, Inc. (MEDS) a Quality of Company score of 4.3/10 across 32 fundamental signals as of 2026-08-27.” Source: circlfi.com/stock/MEDS/ · Methodology
Primary sources for this MEDS valuation
  • Financial statements: DataMEDS AI, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0002030763) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for MEDS as of ; valuations recomputed .